Science and Research

Nicotine promotes e-cigarette vapour-induced lung inflammation and structural alterations

BACKGROUND: Electronic cigarette (e-cigarette) vapour is gaining popularity as an alternative to tobacco smoking and can induce acute lung injury. However, the specific role of nicotine in e-cigarette vapour and its long-term effects on the airways, lung parenchyma and vasculature remain unclear. RESULTS: In vitro exposure to nicotine-containing e-cigarette vapour extract (ECVE) or to nicotine-free e-cigarette vapour extract (NF ECVE) induced changes in gene expression of epithelial cells and pulmonary arterial smooth muscle cells (PASMCs), but ECVE in particular caused functional alterations (e.g. a decrease in human and mouse PASMC proliferation by 29.3±5.3% and 44.3±8.4%, respectively). Additionally, acute inhalation of nicotine-containing e-cigarette vapour (ECV) but not nicotine-free e-cigarette vapour (NF ECV) increased pulmonary endothelial permeability in isolated lungs. Long-term in vivo exposure of mice to ECV for 8 months significantly increased the number of inflammatory cells, in particular lymphocytes, compared to control and NF ECV in the bronchoalveolar fluid (BALF) (ECV: 853.4±150.8 cells·mL(-1); control: 37.0±21.1 cells·mL(-1); NF ECV: 198.6±94.9 cells·mL(-1)) and in lung tissue (ECV: 25.7±3.3 cells·mm(-3); control: 4.8±1.1 cells·mm(-3); NF ECV: 14.1±2.2 cells·mm(-3)). BALF cytokines were predominantly increased by ECV. Moreover, ECV caused significant changes in lung structure and function (e.g. increase in airspace by 17.5±1.4% compared to control), similar to mild tobacco smoke-induced alterations, which also could be detected in the NF ECV group, albeit to a lesser degree. In contrast, the pulmonary vasculature was not significantly affected by ECV or NF ECV. CONCLUSIONS: NF ECV components induce cell type-specific effects and mild pulmonary alterations, while inclusion of nicotine induces significant endothelial damage, inflammation and parenchymal alterations.

  • Roxlau, E. T.
  • Pak, O.
  • Hadzic, S.
  • Garcia-Castro, C. F.
  • Gredic, M.
  • Wu, C. Y.
  • Schäffer, J.
  • Selvakumar, B.
  • Pichl, A.
  • Spiegelberg, D.
  • Deutscher, J.
  • Bednorz, M.
  • Schäfer, K.
  • Kraut, S.
  • Kosanovic, D.
  • Zeidan, E. M.
  • Kojonazarov, B.
  • Herold, S.
  • Strielkov, I.
  • Guenther, A.
  • Wilhelm, J.
  • Khalifa, M. M. A.
  • Taye, A.
  • Brandes, R. P.
  • Hecker, M.
  • Grimminger, F.
  • Ghofrani, H. A.
  • Schermuly, R. T.
  • Seeger, W.
  • Sommer, N.
  • Weissmann, N.

Keywords

  • Humans
  • Animals
  • Mice
  • Nicotine/adverse effects
  • *Electronic Nicotine Delivery Systems
  • *E-Cigarette Vapor/adverse effects/metabolism
  • *Pneumonia/etiology/metabolism
  • Lung/metabolism
  • Plant Extracts/metabolism/pharmacology
Publication details
DOI: 10.1183/13993003.00951-2022
Journal: Eur Respir J
Number: 6
Work Type: Original
Location: UGMLC
Disease Area: PALI
Partner / Member: JLU, MPI-BN
Access-Number: 37105573

DZL Engagements

chevron-down